DE3479815D1 - Methods for producing mature protein in vertebrate host cells - Google Patents

Methods for producing mature protein in vertebrate host cells

Info

Publication number
DE3479815D1
DE3479815D1 DE8484300298T DE3479815T DE3479815D1 DE 3479815 D1 DE3479815 D1 DE 3479815D1 DE 8484300298 T DE8484300298 T DE 8484300298T DE 3479815 T DE3479815 T DE 3479815T DE 3479815 D1 DE3479815 D1 DE 3479815D1
Authority
DE
Germany
Prior art keywords
protein
vertebrate host
methods
host cells
mature protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8484300298T
Other languages
English (en)
Inventor
Arthur David Levinson
Christian Clinton Simonsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE3479815D1 publication Critical patent/DE3479815D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Saccharide Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sheets, Magazines, And Separation Thereof (AREA)
  • Separation, Sorting, Adjustment, Or Bending Of Sheets To Be Conveyed (AREA)
DE8484300298T 1983-01-19 1984-01-18 Methods for producing mature protein in vertebrate host cells Expired DE3479815D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/459,152 US4713339A (en) 1983-01-19 1983-01-19 Polycistronic expression vector construction

Publications (1)

Publication Number Publication Date
DE3479815D1 true DE3479815D1 (en) 1989-10-26

Family

ID=23823622

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484300298T Expired DE3479815D1 (en) 1983-01-19 1984-01-18 Methods for producing mature protein in vertebrate host cells

Country Status (13)

Country Link
US (1) US4713339A (de)
EP (1) EP0117058B1 (de)
JP (3) JPH0630609B2 (de)
KR (1) KR840007253A (de)
AT (1) ATE46536T1 (de)
AU (1) AU578011B2 (de)
CA (1) CA1301675C (de)
DE (1) DE3479815D1 (de)
DK (1) DK173928B1 (de)
ES (1) ES529022A0 (de)
IE (1) IE55852B1 (de)
NZ (1) NZ206841A (de)
ZA (1) ZA84377B (de)

Families Citing this family (305)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
EP0154539A3 (de) * 1984-03-06 1986-12-30 Eli Lilly And Company Rekombinante DNS-Expressionsvektoren und Verfahren für Genexpression
GB8522977D0 (en) * 1985-09-17 1985-10-23 Fujisawa Pharmaceutical Co Production of insulin-like growth factor 1
IL71691A (en) * 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
CA1275954C (en) * 1984-08-31 1990-11-06 Hing Cheug Wong 3'-expression enhancing fragments and method
IL80511A0 (en) * 1985-11-05 1987-02-27 Genetics Inst Multiply amplifiable vectors for high level expression of exogenous dna
FI870103A (fi) * 1986-01-13 1987-07-14 Genex Corp Producering av humanserum albumin i en bacillus-stam.
CA1297434C (en) * 1986-04-14 1992-03-17 Kenji Murakami Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
JP2585532B2 (ja) * 1986-05-10 1997-02-26 三井東圧化学株式会社 動物細胞の形質転換体及びそれを得る方法並びにその形質転換体を用いてｔ−ＰＡを生産する方法
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
AU1187588A (en) * 1987-01-15 1988-08-10 Codon Genetic Engineering Laboratories Tandem gene eukaryotic expression vectors
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5215896A (en) * 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US5876962A (en) * 1987-08-12 1999-03-02 Natural Environment Research Council Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing such vectors
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JP2576200B2 (ja) * 1988-03-09 1997-01-29 味の素株式会社 生理活性タンパク質の製造法
US4892871A (en) * 1988-04-12 1990-01-09 The General Hospital Corporation Azido-substituted octopamine agonists and the use thereof to control invertebrate pests
WO1990001550A1 (en) * 1988-07-29 1990-02-22 Zymogenetics, Inc. High efficiency translation of polycistronic messages in eucaryotic cells
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) * 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US20020168750A1 (en) * 1988-12-23 2002-11-14 James Rasmussen Enzymatically active recombinant glucocerebrosidase
US5549892A (en) * 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
CA2050601C (en) 1989-05-10 2000-09-19 Stephen J. Hoffman Production in bacteria and yeast of hemoglobin and analogues thereof
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US6203976B1 (en) 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
KR100194562B1 (ko) * 1989-07-18 1999-06-15 로버트 반 노스트랜드 전사단계에서의 유전자 발현의 조절방법 및 유전자 발현 조절 인자로서 작용할수 있는 화학물의 발견방법
US7247475B2 (en) * 1989-07-28 2007-07-24 Wyeth Method for producing monoclonal antibodies
US6475787B1 (en) * 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
DE69130494T2 (de) * 1990-06-11 1999-07-08 Nakamura, Toshikazu, Fukuoka Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
WO1992013063A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
WO1992013091A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
AU1258292A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating expression of hematopoietic growth factor genes
JPH0516500U (ja) * 1991-08-09 1993-03-02 富士通テン株式会社 車載用機器の取付構造
CA2122717C (en) * 1991-11-08 2003-07-15 David C. Anderson Hemoglobins as drug delivery agents
WO1994021669A1 (en) * 1993-03-18 1994-09-29 Medclone, Inc. Antigen related to inflammatory diseases
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DK0848755T4 (da) 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
EP0904366A1 (de) 1996-04-01 1999-03-31 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptiden
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
DK1632574T3 (da) 1996-10-16 2011-02-28 Zymogenetics Inc Fibroblast-vækstfaktor homologer
DE69737457T2 (de) 1997-01-31 2007-11-29 Genentech, Inc., South San Francisco O-fukosyltransferase
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
JP2001511653A (ja) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
CA2293724C (en) 1997-06-05 2010-02-02 Xiaodong Wang Apaf-1, the ced-4 human homolog, an activator of caspase-3
JP2002508663A (ja) 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ATE393222T1 (de) 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
ATE424459T1 (de) 1997-10-10 2009-03-15 Genentech Inc Apo-3 ligand
EP2033970A3 (de) 1997-10-29 2009-06-17 Genentech, Inc. WNT-1-induzierbare Gene
ES2313756T3 (es) 1997-10-29 2009-03-01 Genentech, Inc. Usos de polipeptido secretado wisp-1 inducido por wnt-1.
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
DE69840105D1 (de) 1997-11-21 2008-11-20 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
ATE411385T1 (de) 1998-01-15 2008-10-15 Genentech Inc Apo-2 ligand
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
DK2016951T3 (da) 1998-03-17 2012-09-24 Genentech Inc VEGF- og BMP1-homologe polypeptider
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
DK1076703T4 (da) 1998-05-15 2011-03-28 Genentech Inc Terapeutiske anvendelser af IL-17-homologe polypeptider
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
DK1115862T3 (da) 1998-09-23 2009-11-16 Zymogenetics Inc Cytokinreceptor Zalpha11
WO2000034474A2 (en) 1998-12-07 2000-06-15 Zymogenetics, Inc. Growth factor homolog zvegf3
EP2075335A3 (de) 1998-12-22 2009-09-30 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
EP2319929A1 (de) 1998-12-23 2011-05-11 Genentech, Inc. Mit IL-1 in Zusammenhang stehende Polypeptide
NZ512753A (en) 1999-01-07 2003-10-31 Zymogenetics Inc Soluble receptor BR43x2 related proteins useful for inhibiting ztnf4
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
ATE377076T1 (de) 1999-03-09 2007-11-15 Zymogenetics Inc Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
EP1956030B1 (de) 1999-06-15 2009-11-11 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
MXPA01013236A (es) 1999-06-28 2002-06-21 Genentech Inc Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
CA2490853A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897943B1 (de) 1999-12-23 2011-12-14 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP1242600B1 (de) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Zytokin zcyt018
ES2323220T3 (es) 2000-01-13 2009-07-09 Genentech, Inc. Polipeptidos humanos stra6.
ATE329610T1 (de) 2000-02-16 2006-07-15 Genentech Inc Anti-april antikörper und hybridomazellen
US6737420B2 (en) 2000-03-23 2004-05-18 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
EP2042597B1 (de) 2000-06-23 2014-05-07 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
CA2709771A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2258725A3 (de) 2000-06-26 2014-09-17 ZymoGenetics, L.L.C. Cytokinrezeptor zcytor17
EP1717316B1 (de) 2000-06-30 2008-08-13 ZymoGenetics, Inc. Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
US7034182B2 (en) 2000-06-30 2006-04-25 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
AU7025201A (en) 2000-07-03 2002-01-14 Gala Design Inc Expression vectors
US6677500B2 (en) 2000-08-15 2004-01-13 Board Of Trustees Of The University Of Illinois Ungulates expressing exogenous IGF-I in their milk
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
WO2002022776A2 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
JP2004529640A (ja) 2001-03-22 2004-09-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ凝固因子誘導体
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
ES2372321T3 (es) 2001-06-20 2012-01-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
HU230373B1 (hu) 2001-08-29 2016-03-29 Genentech Inc Mitogén aktivitású Bv8-nukleinsavak és polipeptidek
EP2151244A1 (de) 2001-09-18 2010-02-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
PL368619A1 (en) 2001-09-27 2005-04-04 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
IL161051A0 (en) 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
DK2279753T3 (en) 2001-10-10 2015-11-23 Novo Nordisk As The conversion of peptides and glycokonjugering
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
DK1451322T3 (da) 2001-11-05 2010-02-01 Zymogenetics Inc Il-21-antagonister
PT1450847E (pt) 2001-11-13 2011-01-05 Genentech Inc Formulações de ligando de apo2/trail e suas utilizações
EP2022799A2 (de) 2001-11-16 2009-02-11 Biogen Idec Inc. Polycistronische Expression von Antikörpern
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
MXPA04006554A (es) 2002-01-02 2005-03-31 Genentech Inc Composiciones y metodos para diagnostico y tratamiento de tumor.
US7494804B2 (en) 2002-01-18 2009-02-24 Zymogenetics, Inc. Polynucleotide encoding cytokine receptor zcytor17 multimer
RU2360923C2 (ru) 2002-01-18 2009-07-10 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ATE431406T1 (de) 2002-02-25 2009-05-15 Genentech Inc Neuer typ-1-cytokinrezeptor glm-r
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
EP1571968A4 (de) 2002-04-16 2007-10-17 Genentech Inc Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
WO2003089603A2 (en) 2002-04-19 2003-10-30 Zymogenetics, Inc. Cytokine receptor
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method
JP4574350B2 (ja) 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
EP1572130A4 (de) 2002-07-08 2008-07-02 Genentech Inc Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
EP2085096A3 (de) 2002-09-11 2009-08-12 Genentech, Inc. Neuartige Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
EP2444409A2 (de) 2002-09-16 2012-04-25 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1581169A4 (de) 2002-11-08 2008-09-17 Genentech Inc Zusammensetzungen und verfahren zurbehandlung von erkrankungen in verbindung mit natürlichen killerzellen
US20050019925A1 (en) * 2002-11-14 2005-01-27 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
EP1611236A1 (de) 2003-03-18 2006-01-04 Novo Nordisk Health Care AG Verfahren zur herstellung von serinproteasen mit gla-rest
EP1608967A4 (de) 2003-04-01 2006-08-09 Genentech Inc Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
CA2519408C (en) 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
CA2522213A1 (en) * 2003-04-08 2004-10-28 Dante J. Marciani Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US20050095243A1 (en) 2003-06-05 2005-05-05 Genentech, Inc. Combination therapy for B cell disorders
AU2004245175C1 (en) 2003-06-10 2010-03-18 Biogen Ma Inc. Improved secretion of neublastin
HUE045709T2 (hu) 2003-07-08 2020-01-28 Genentech Inc Antagonista antitestek IL-17A/F heterológ polipeptidekhez
EP2251353B1 (de) 2003-08-07 2013-03-06 ZymoGenetics, Inc. Homogene Präparate von IL-29
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005024015A1 (en) 2003-09-04 2005-03-17 Medarex, Inc. Expression vector
CN1863908B (zh) 2003-09-09 2010-08-04 诺和诺德医疗保健公司 凝固因子ⅶ多肽
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
CN1926237A (zh) * 2004-01-28 2007-03-07 森托尼克斯制药有限公司 用于治疗不育症的异二聚体促卵泡激素－Fc(FSH－Fc)融合蛋白
EP1732946B1 (de) 2004-03-08 2011-07-27 ZymoGenetics, Inc. Dimere fusionsproteine und materialien und verfahren zu deren herstellung
ES2532610T3 (es) 2004-07-26 2015-03-30 Genentech, Inc. Procedimientos y composiciones para modular la activación del factor de crecimiento de hepatocitos
WO2006012644A2 (en) 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
JP2008540569A (ja) 2005-05-12 2008-11-20 ザイモジェネティクス， インコーポレイテッド 免疫系を調整するためにＢ７ファミリーメンバーであるｐＮＫｐ３０を使用する方法
AU2006255686A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
UA93516C2 (ru) * 2005-08-09 2011-02-25 Займоджинетикс, Инк. Способы лечения b-клеточных злокачественных образований c помощью слитой молекулы taci-ig
AU2006278227B2 (en) 2005-08-09 2011-10-20 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
WO2007021423A2 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US20090055942A1 (en) 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
CA2633661C (en) 2005-12-21 2019-06-04 University Of North Carolina At Chapel Hill Method of producing biologically active vitamin k dependent proteins by recombinant methods
AU2007233263A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2007103447A2 (en) 2006-03-06 2007-09-13 Humagene, Inc. A method for the preparation of recombinant human thrombin
EP2650305B1 (de) 2006-03-24 2024-05-08 Bioverativ Therapeutics Inc. PC5 als Faktor-IX-Propeptid-verarbeitendes Enzym
EP2007428A2 (de) 2006-04-05 2008-12-31 Genentech, Inc. Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
WO2008036437A2 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2027291A2 (de) 2006-04-27 2009-02-25 Pikamab, Inc. Verfahren und zusammensetzungen für antikörpertherapie
NZ572373A (en) * 2006-05-15 2012-02-24 Ares Trading Sa Methods for treating rheumatoid arthritis using a taci-ig fusion molecule
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
WO2008005847A2 (en) 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
DK2495307T5 (en) 2006-07-13 2018-07-16 Wyeth Llc Preparation of coagulation factor IX with improved glycosylation pattern
KR20090105913A (ko) 2006-11-02 2009-10-07 다니엘 제이 카폰 이동 부분을 갖는 하이브리드 면역글로불린
US8685720B2 (en) 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
EP2436781B1 (de) 2007-02-22 2015-10-07 Genentech, Inc. Verfahren für den Nachweis von entzündlicher Darmerkrankung
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
JP6050927B2 (ja) 2007-04-26 2016-12-21 シーエヌジェイ ホールディングス，インコーポレイテッド 高シアル酸含量を有する組換えビタミンｋ依存性タンパク質およびその調製方法
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
AU2008284047A1 (en) * 2007-08-09 2009-02-12 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
PL2233149T3 (pl) 2007-10-16 2016-08-31 Zymogenetics Inc Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
HUE029869T2 (en) 2008-01-31 2017-04-28 Genentech Inc Anti-CD79B antibodies and immunoconjugates, as well as application procedures
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
KR20180132156A (ko) 2008-04-09 2018-12-11 제넨테크, 인크. 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
EP2623112B1 (de) 2008-06-27 2015-03-04 Zymogenetics, Inc. Lösliche hybride FC-Gamma-Rezeptoren und zugehörige Verfahren
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
KR20110056323A (ko) 2008-09-15 2011-05-26 제넨테크, 인크. 세포 오스몰농도를 조절하기 위한 조성물 및 방법
US9702877B2 (en) 2008-10-31 2017-07-11 Quest Diagnostics Investments Incorporated BCR-ABL variants
KR101655492B1 (ko) 2008-12-22 2016-09-07 국립대학법인 홋가이도 다이가쿠 동물세포를 사용해서 외래유전자 유래 단백질을 대량으로 생산하기 위한 발현 벡터, 및 그의 이용
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
AU2010272483B2 (en) 2009-07-17 2016-07-21 Omeros Corporation MASP isoforms as inhibitors of complement activation
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
WO2011041308A1 (en) 2009-09-30 2011-04-07 Quest Diagnostics Investments Incorporated Bcr-abl truncation mutations
CN102656266B (zh) 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
EP2494040B1 (de) 2009-10-30 2018-08-29 Aptevo BioTherapeutics LLC Verfahren zur herstellung rekombinanter vitamin-k-abhängiger proteine
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
TWI537383B (zh) 2009-11-30 2016-06-11 建南德克公司 診斷及治療腫瘤之組合物及方法
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP2580238A1 (de) 2010-06-09 2013-04-17 Zymogenetics, Inc. Dimere vstm3-fusionsproteine sowie zugehörige zusammensetzungen und verfahren
WO2011161491A1 (en) 2010-06-25 2011-12-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of respiratory tract infections
EP3508573A1 (de) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systeme für faktor viii-verarbeitung und verfahren davon
US20130150554A1 (en) 2010-08-20 2013-06-13 Wyeth Llc Cell culture of growth factor-free adapted cells
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
EP2616481A4 (de) 2010-09-15 2014-04-02 Aligna Technologies Inc Bioproduktion aromatischer chemikalien aus von lignin abgeleiteten verbindungen
US8603740B2 (en) 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
MX2013012716A (es) 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
CA2848204C (en) 2011-09-12 2023-04-04 Amunix Operating Inc. Glucagon-like peptide-2 compositions and methods of making and using same
US20140322758A1 (en) 2011-10-21 2014-10-30 Pfizer Inc. Addition of iron to improve cell culture
US8748097B1 (en) 2011-12-02 2014-06-10 President And Fellows Of Harvard College Identification of agents for treating calcium disorders and uses thereof
BR112014017165B1 (pt) 2012-01-12 2023-05-02 Bioverativ Therapeutics Inc Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos
CN104220602B (zh) 2012-02-01 2018-10-30 合成基因组股份有限公司 用于合成错误最小化核酸分子的材料和方法
US11787844B2 (en) 2012-02-09 2023-10-17 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
ES2771208T3 (es) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
EP2841087B1 (de) 2012-04-27 2017-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Antagonisten gegen den vaskulären endothelialen wachstumsfaktor und verfahren zu deren verwendung
EP2848687B1 (de) 2012-04-27 2017-09-13 JCR Pharmaceuticals Co., Ltd. Neuartiger expressionsvektor
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US20150307865A1 (en) 2012-10-15 2015-10-29 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
CA2892038C (en) 2012-11-20 2021-12-28 Darrel W. Stafford Methods and compositions for modified factor ix proteins
WO2014115087A2 (en) 2013-01-22 2014-07-31 Cencor Biotech Ltd. A method for the preparation of recombinant human prothrombin and fibrinogen
KR102426481B1 (ko) 2013-03-15 2022-07-27 제넨테크, 인크. IL-22 폴리펩티드 및 IL-22 Fc 융합 단백질 및 사용 방법
EP4039281A1 (de) 2013-03-15 2022-08-10 Biomolecular Holdings LLC Hybrides immunglobulin mit nichtpeptidylverbindung
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
SG10201913738YA (en) 2013-06-28 2020-03-30 Bioverativ Therapeutics Inc Thrombin cleavable linker with xten and its uses thereof
EP3043813B1 (de) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN105722523B (zh) 2013-11-15 2022-06-14 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
DK3091997T5 (da) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
PT3116486T (pt) 2014-03-14 2020-03-12 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
WO2015140708A1 (en) 2014-03-19 2015-09-24 Pfizer Inc. Method of cell culture
US10954282B2 (en) 2014-12-09 2021-03-23 Wentao Zhang NBP158 and uses thereof
AU2016215124B2 (en) 2015-02-06 2020-08-06 The University Of North Carolina At Chapel Hill Optimized human clotting Factor VIII gene expression cassettes and their use
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
DK3298036T3 (da) 2015-05-22 2022-06-07 CSL Behring Lengnau AG Fremgangsmåder til forberedelse af modificeret von Willebrand faktor
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
EP3328881B1 (de) 2015-09-08 2019-08-28 Theripion, Inc. Apoa-1-fusionspolypeptide sowie zugehörige zusammensetzungen und verfahren
CA3214798A1 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
EP3184149A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Lösliches glycoprotein v zur behandlung von thrombose-erkrankungen
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
EP3196295A1 (de) 2016-01-25 2017-07-26 Albert-Ludwigs-Universität Freiburg Verfahren zur herstellung von nierenzellen aus fibroblasten
BR112018070063A2 (pt) 2016-04-05 2019-02-12 Pfizer Inc. processo de cultivo de células
CN109328069B (zh) 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
EP3538133B1 (de) 2016-11-11 2021-02-17 CSL Behring Lengnau AG Verkürzte von-willebrand-faktor-polypeptide zur behandlung von hämophilie
CA3043397A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
PL3641800T3 (pl) 2017-06-22 2024-03-18 CSL Behring Lengnau AG Modulacja immunogenności fviii przez skrócony vwf
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
RU2756100C1 (ru) 2017-12-20 2021-09-28 Харбор Байомед (Шанхай) Ко., Лтд Антитела, связывающие ctla-4, и их применение
WO2019132765A1 (en) 2017-12-27 2019-07-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
JP7349995B2 (ja) 2018-01-26 2023-09-25 ジェネンテック， インコーポレイテッド ＩＬ－２２ Ｆｃ融合タンパク質及び使用方法
HRP20221448T1 (hr) 2018-01-26 2023-01-20 F. Hoffmann - La Roche Ag Il-22 fc pripravci i postupci njihove primjene
WO2019165140A1 (en) 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
NZ769677A (en) 2018-05-18 2024-07-05 Bioverativ Therapeutics Inc Methods of treating hemophilia a
US20210278406A1 (en) 2018-07-13 2021-09-09 Varct Diagnostic Aps Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
CA3121884A1 (en) 2018-12-06 2020-06-11 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2021040610A1 (en) 2019-08-26 2021-03-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2021262081A1 (en) 2020-06-22 2021-12-30 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and combinations for use in the treatment of cancer
JP2023535604A (ja) 2020-07-30 2023-08-18 ファイザー・インク 遺伝子複製を有する細胞およびその使用
EP4203989A2 (de) 2020-09-03 2023-07-05 Rampart Bioscience, Inc. Lösliche alkalische phosphatasekonstrukte und expressionsvektoren mit einem polynukleotid zur codierung löslicher alkalischer phosphatasekonstrukte
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022178090A2 (en) 2021-02-19 2022-08-25 Theripion, Inc. Dnase fusion polypeptides and related compositions and methods
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
EP4380969A1 (de) 2021-08-02 2024-06-12 Pfizer Inc. Verbesserte expressionsvektoren und verwendungen davon
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
CN116554303A (zh) 2022-01-30 2023-08-08 斯莱普泰(上海)生物医药科技有限公司 载脂蛋白E的C端片段及其在抑制γ分泌酶酶活中的应用
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2024148328A2 (en) 2023-01-06 2024-07-11 Aptevo Research And Development Llc Bispecific pd-l1 and cd40 binding molecules and uses thereof
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2963374D1 (en) * 1978-10-10 1982-09-09 Univ Leland Stanford Junior Recombinant dna, method for preparing it and production of foreign proteins by unicellular hosts containing it
AU546577B2 (en) * 1980-02-25 1985-09-05 Trustees Of Columbia University, The Use of eucaryotic promoter sequences in the production of proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0054223A3 (de) * 1980-12-08 1983-01-12 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Plasmid-Vektoren für eukaryotische Zellen und Verfahren zum Selektieren von transfektierten eukaryotischen Zellen
FR2500847B1 (fr) * 1981-03-02 1985-09-13 Pasteur Institut Marqueurs genetiques selectifs pour cellules eucaryotes, procede de mise en oeuvre de tels marqueurs et application des cellules contenant un tel marqueur a la fabrication de proteines determinees apres leur transformation par un adn correspondant
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
AU572108B2 (en) * 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4670399A (en) * 1983-01-31 1987-06-02 Stauffer Chemical Co. Hybrid plasmid with marker

Also Published As

Publication number Publication date
IE55852B1 (en) 1991-01-30
ES8507179A1 (es) 1985-09-01
ES529022A0 (es) 1985-09-01
JPH06165672A (ja) 1994-06-14
AU578011B2 (en) 1988-10-13
JP2719512B2 (ja) 1998-02-25
CA1301675C (en) 1992-05-26
EP0117058A3 (en) 1986-02-12
NZ206841A (en) 1987-06-30
JPH0630609B2 (ja) 1994-04-27
AU2353184A (en) 1984-07-26
JPH08252091A (ja) 1996-10-01
KR840007253A (ko) 1984-12-06
DK20984A (da) 1984-07-20
ZA84377B (en) 1985-02-27
EP0117058B1 (de) 1989-09-20
DK173928B1 (da) 2002-02-25
DK20984D0 (da) 1984-01-18
JP2557605B2 (ja) 1996-11-27
JPS59173096A (ja) 1984-09-29
US4713339A (en) 1987-12-15
IE840095L (en) 1984-07-19
EP0117058A2 (de) 1984-08-29
ATE46536T1 (de) 1989-10-15

Similar Documents

Publication Publication Date Title
DE3479815D1 (en) Methods for producing mature protein in vertebrate host cells
ES8505412A1 (es) Un metodo para producir eficazmente un factor de crecimiento similar a insulina humana
GB2197324B (en) Process for the production of a polypeptide
EP0343783A3 (en) Method for producing cells containing stably integrated foreign dna at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign dna
UA27706C2 (uk) Спосіб одержання гетерологічного поліпептиду
ES8602138A1 (es) Metodo de controlar la expresion de un gen que codifica una proteinaheterologa deseada.
GB2137631B (en) Multichain polypeptides and processes for their production
EP0180615A4 (de) Atrielle natriumuretische/gefässerweiterende polypeptide.
AU600253B2 (en) Expression of eucaryotic proteins
KR840008697A (ko) 상동 효모 신호를 이용한 이종단백질의 합성, 분비 및 표현매개체 제조방법
ES8306177A1 (es) Un metodo de proporcionar una muestra de un gen fusionado que codifica un polipeptido eucariotico o procariotico deseado.
ATE315644T1 (de) Für das igg-fc-bindende protein kodierendes gen
IL94422A0 (en) Saf polypeptide,gene coding therefor,saf promoter and expression methods for expressing foreign dna sequences in streptomyces
CA1312566C (en) Method for increasing the expression of polypeptides in recombinant cell culture
GR3016996T3 (en) Method for the preparation of a protein by yeast using an inductible system, vectors and corresponding transformed strains.
ES8405842A1 (es) Procedimiento de producir razas estables de celulas de mamiferos
GR3020035T3 (en) Mammalian cell derived autonomously replicating sequence DNA fragments having affinity to DNA binding proteins
EP0315950A3 (de) Verfahren zur Züchtung von Zellen, welche rekombinantes Protein exprimieren
ATA435083A (de) Das polypeptid interleukin-2 kodierendes gen, rekombinante, dieses gen enthaltende dna, diese rekombinante dna aufweisende zellinien und verfahren zur herstellung von interleukin-2 unter verwendung der genannten zellen
ES2054608T3 (es) Un metodo para la expresion de genes en levadura y fragmentos de adn asi como plasmidos que comprenden dichos fragmentos de adn para uso cuando se lleva a cabo dicho metodo.
EP0165759A3 (de) Säugetierpromotoren verwendbar in Hefeexpression
DK145595A (da) Fremgangsmåde til selektion af transficerede hvirveldyrceller

Legal Events

Date Code Title Description
8364 No opposition during term of opposition